Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

Journal of Psychopharmacology
Karla MayfieldSamantha Hollingworth

Abstract

Clozapine is the most effective antipsychotic, but its use is tempered by adverse metabolic effects such as weight gain, glucose intolerance and type II diabetes. Current interventions do not facilitate compelling or sustained improvement in metabolic status. Recent studies suggest that glucagon-like peptide-1 (GLP-1) may play a key role in clozapine's metabolic effects, possibly suggesting that clozapine-associated obesity and diabetes are mediated independently through reduced GLP-1. As a result, GLP-1 agonists could show promise in reversing antipsychotic-induced metabolic derangements, providing mechanistic justification that they may represent a novel approach to treat, and ultimately prevent, both diabetes and obesity in patients on clozapine. GLP-1 agonists are already used for diabetes, and they provide a unique combination of glycaemic improvement and metabolically relevant weight loss in diabetic and non-diabetic patients, in the context of a currently favourable safety profile. Using GLP-1 agonists for clozapine-associated obesity and diabetes could be a potentially effective intervention that may reduce cardiometabolic morbidity and mortality in this vulnerable patient population.

References

Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Wetterling
Apr 5, 2002·Journal of Molecular Neuroscience : MN·Abba J KastinWeihong Pan
Jan 14, 2003·The Journal of Clinical Psychiatry·Diana O Perkins
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·Shitij KapurJose N Nobrega
Mar 29, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·David B AllisonDiana D McDonnell
May 30, 2003·American Journal of Physiology. Endocrinology and Metabolism·Ronald L PrigeonDavid A D'Alessio
Jan 18, 2005·Schizophrenia Research·John Hennen, Ross J Baldessarini
Mar 23, 2005·Regulatory Peptides·Carolyn F Deacon
Jul 15, 2005·The Journal of Clinical Psychiatry·J Steven LambertiKaren Wiener
Mar 7, 2006·Cell Metabolism·Daniel J Drucker
Oct 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen L HouseknechtHans Rollema
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·L M SpelmanJ H Thakore
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Julia SacherSiegfried Kasper
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Apr 10, 2008·Journal of Neurochemistry·Yu-Kyong ShinSteven D Munger
May 8, 2008·The Journal of Clinical Endocrinology and Metabolism·Karen Elkind-HirschRajat Bhushan
Jun 27, 2008·Schizophrenia Research·Kirsten LykkegaardLotte Bjerre Knudsen
Jul 4, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·J H BestM Peyrot
Nov 13, 2009·The Journal of Clinical Endocrinology and Metabolism·Solrun VidarsdottirHanno Pijl
Mar 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lawrence MaayanChristoph U Correll
Apr 3, 2010·Neurobiology of Aging·Simon GenglerChristian Hölscher
Aug 3, 2010·Trends in Pharmacological Sciences·Heidi N BoydaAlasdair M Barr
Dec 15, 2010·Clinical Pharmacokinetics·Mark FinemanLeigh MacConell
Dec 15, 2010·BMC Endocrine Disorders·Deepson S ShyangdanNorman R Waugh
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen
Apr 29, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Paula L McCleanChristian Hölscher

❮ Previous
Next ❯

Citations

Mar 17, 2016·The Australian and New Zealand Journal of Psychiatry·Dan SiskindMark Ashford
Oct 1, 2019·Expert Opinion on Drug Safety·Wade MarteeneDan Siskind
Mar 1, 2017·Frontiers in Psychiatry·Adonis SferaMichael Cummings
May 17, 2017·BJPsych Open·Alejandro Porras-SegoviaSukhwinder S Shergill
Apr 12, 2017·Frontiers in Endocrinology·Pratyusha NaiduElif I Ekinci
Mar 16, 2021·Frontiers in Endocrinology·Jessica W Y YuenAlasdair M Barr
Apr 27, 2021·Expert Opinion on Drug Metabolism & Toxicology·Jacob T BrownJeffrey R Bishop
May 5, 2021·The International Journal of Neuroscience·LongQing ZhangXueBi Tian
Aug 21, 2021·Scientific Reports·G HorvathS Benyhe
Nov 3, 2020·American Journal of Therapeutics·Ahmed NaguyBibi Alamiri

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Software Mentioned

DURATION
AMIGO
LEAD

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.